Programmed cell death protein 1 and programmed cell death ligand 1 (PD-1/PD-L1) inhibitors, as an important class of immune checkpoint inhibitors (ICIs), have become increasingly prominent in cancer treatment. This evidence concerns the gene CD274 and cancer.